Zero cervical cancer deaths in vaccinated young women
A landmark long-term study from Scotland found zero cervical cancer deaths among women who received the HPV vaccine in childhood (ages 12–13), since the national programme began in 2008
Supplementary data from England (2020–2024) showed no cervical cancer deaths in women aged 20–24 — the first time on record — whereas approximately 23 deaths were expected in this age group without vaccination
The findings, published in the Journal of the National Cancer Institute, confirm that the HPV vaccine reduces the risk of cervical cancer death before age 30 to effectively zero
An estimated 200 lives have been saved in England alone since the vaccination programme began
India launched its own nationwide HPV Vaccination Programme on 28 February 2026, targeting approximately 1.15 crore girls aged 14 years at government facilities, free of cost
Human Papillomavirus (HPV) and Cervical Cancer
Human Papillomavirus (HPV) is a group of more than 200 related viruses, of which certain high-risk strains cause nearly all cases of cervical cancer. HPV types 16 and 18 account for over 80% of cervical cancer cases in India. Persistent HPV infection leads to cellular changes that, over years, can progress to cervical cancer.
Key Details
- HPV is a DNA virus; cervical cancer is the only major cancer that is almost entirely caused by a single infectious agent
- High-risk HPV strains: Types 16, 18 (cancer-causing); Low-risk strains: Types 6, 11 (warts)
- Gardasil (quadrivalent) — used in India's national programme — protects against HPV 6, 11, 16, 18
- A single dose of Gardasil-4 provides 93–100% effectiveness against the HPV types responsible for cervical cancer
- Cervical cancer is the second most common cancer among women aged 15–44 in India
The Scotland study validates that a population-level vaccination programme at ages 12–13 (before sexual debut) provides near-complete protection against cervical cancer mortality — the mechanism India is now deploying at scale.
India's Cervical Cancer Burden and National Programme
India bears a disproportionately large share of the global cervical cancer burden, making the Scotland study's findings particularly relevant to Indian public health policy.
Key Details
- India accounts for approximately 25% of global cervical cancer deaths
- Annual burden: ~1.24 lakh new cases and ~77,000 deaths per year (ICMR data)
- At-risk population: 511 million women aged 15 and above
- India launched its nationwide HPV vaccination programme on 28 February 2026 (announced in the Union Budget 2024-25)
- Vaccine used: Gardasil-4 (quadrivalent), provided free at government health facilities
- Target: ~1.15 crore girls aged 14 years across all States and UTs
- India becomes one of 160+ countries with HPV vaccination in national immunisation schedules
India's programme mirrors the Scottish model — targeting pre-adolescent girls before HPV exposure — making the Scotland study a direct predictive template for what India could achieve within a decade.
Universal Immunisation Programme (UIP) and Health Policy
India's Universal Immunisation Programme (UIP) is one of the largest public health programmes in the world, covering vaccines for 12 vaccine-preventable diseases.
Key Details
- UIP is administered under the National Health Mission (NHM)
- The HPV vaccine addition represents the first cancer-prevention vaccine added to India's UIP
- Under the National Health Policy 2017, India targets elimination of cervical cancer
- WHO's global strategy (2020) targets: 90% girls vaccinated by age 15; 70% women screened; 90% women identified with disease treated — all by 2030 (the "90-70-90" strategy)
- CERVAVAC — India's indigenously developed quadrivalent HPV vaccine (by Serum Institute of India) — received DCGI approval in 2022 and is being evaluated for the national programme
Adding HPV to UIP aligns India with WHO's global cervical cancer elimination strategy and demonstrates the translation of science-based evidence directly into national health policy.
Vaccine Preventable Diseases and Herd Immunity
The Scotland study also demonstrates the public health concept of herd immunity: even women who were not vaccinated are benefiting from reduced HPV circulation in the population as vaccination rates rise.
Key Details
- Herd immunity threshold for HPV: Estimated at 80–85% vaccination coverage
- Scotland achieved >90% HPV vaccination coverage among eligible girls in many cohorts
- The study represents a "real-world effectiveness" study — more policy-relevant than clinical trials under controlled conditions
- Cancer prevention through vaccines belongs to the category of primary prevention (preventing disease before it occurs), as opposed to secondary prevention (screening) or tertiary prevention (treatment)
India's challenge is achieving sufficient coverage across all states, including remote and high-poverty areas, to replicate the Scotland effect at scale.
- Scotland HPV vaccination programme started: 2008 (girls aged 12–13)
- Cervical cancer deaths in vaccinated cohort (Scotland): 0 (zero)
- Expected cervical cancer deaths in England (ages 20–24, 2020–2024) without vaccine: ~23; Actual: 0
- Estimated lives saved in England to date: ~200
- India's annual cervical cancer cases: ~1.24 lakh; deaths: ~77,000
- India's share of global cervical cancer deaths: ~25%
- India HPV vaccination programme launch: 28 February 2026
- Vaccine used in India: Gardasil-4 (quadrivalent HPV vaccine)
- India's target cohort: ~1.15 crore girls aged 14 years
- HPV types causing 80%+ cervical cancer in India: Types 16 and 18
- Indigenous vaccine: CERVAVAC (Serum Institute of India) — DCGI approved 2022
- Countries with HPV in national immunisation schedules: 160+
- WHO 90-70-90 elimination strategy target year: 2030